Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
KYORIN Pharmaceutical Co.,Ltd. ( (JP:4569) ) has provided an announcement.
KYORIN Pharmaceutical Co., Ltd. has announced an option agreement with BIODOL Therapeutics to potentially license BDT272, a novel pain treatment. This agreement allows KYORIN to develop and commercialize BDT272 in Japan and parts of Asia, excluding China. BDT272 is designed to inhibit the FLT3 receptor tyrosine kinase, which plays a role in neuropathic pain, potentially offering a new treatment for chronic pain conditions. The impact on KYORIN’s business performance for the fiscal year ending March 2025 is expected to be negligible.
More about KYORIN Pharmaceutical Co.,Ltd.
KYORIN Pharmaceutical Co., Ltd. is a company that specializes in the pharmaceutical industry, focusing on the development and commercialization of new drugs, particularly in the field of pain treatment. The company aims to address medical needs with high-value therapeutic solutions.
YTD Price Performance: -3.39%
Average Trading Volume: 86,337
Technical Sentiment Consensus Rating: Buy
Current Market Cap: Yen83.32B
For an in-depth examination of 4569 stock, go to TipRanks’ Stock Analysis page.
